Y-mAbs to Host Annual Research and Development Day in New York
NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company today announced that it will host its annual Research and Development Day in New York, NY on December 14, 2022, at 9:00 am ET. The event will feature presentations of the Company, its clinical development, and advanced product pipeline.
A question-and-answer session will follow the formal presentations. To register for the event, please click here.
About DANYELZA® (naxitamab-gqgk)
Researchers at Memorial Sloan Kettering Cancer Center (“MSK”) developed DANYELZA, which is exclusively licensed by MSK to Y-mAbs. MSK has institutional financial interests related to the compound and Y-mAbs.
DANYELZA®, OMBLASTYS® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc.
+1 646 885 8505
E-mail: [email protected]
Building STIR/SHAKEN services with OpenSIPS 3.3
Best Practices for Multi-Cloud Consumption and SaaS Billing
Registration Counters Open